Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.6186
-0.1650 (-21.06%)
Sep 4, 2025, 3:48 PM - Market open
Cosmos Health Revenue
Cosmos Health had revenue of $14.75M in the quarter ending June 30, 2025, with 11.65% growth. This brings the company's revenue in the last twelve months to $55.09M, down -2.41% year-over-year. In the year 2024, Cosmos Health had annual revenue of $54.43M with 1.97% growth.
Revenue (ttm)
$55.09M
Revenue Growth
-2.41%
P/S Ratio
0.35
Revenue / Employee
$369,755
Employees
149
Market Cap
18.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
COSM News
- 17 days ago - Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025 - GlobeNewsWire
- 23 days ago - Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy - GlobeNewsWire
- 4 weeks ago - Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy - GlobeNewsWire
- 2 months ago - Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech - GlobeNewsWire
- 4 months ago - RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - GlobeNewsWire
- 4 months ago - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven - GlobeNewsWire
- 4 months ago - Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units - GlobeNewsWire
- 4 months ago - Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq - GlobeNewsWire